SEC Form 4 · accession 0001209191-18-014220
SANGAMO THERAPEUTICS, INC · SGMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Saira Ramasastry
Director
Period of report
Feb 26, 2018
Accepted (ET)
Feb 27, 2018 · 6:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001233
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 26, 2018 | M | 9,450 | $5.03 | A | 9,450 | D | |
| Common StockF1 | Feb 26, 2018 | S | 9,450 | $24.8762 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $5.03 | Feb 26, 2018 | M | 9,450 | D | — | Jun 20, 2022 | Common Stock | 9,450 | 0 | D |
Explanation of responses
- F1The price reported is a weighted average price. The shares were sold at prices ranging from $24.85 to $24.905 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F2Option is fully vested and exercisable.